Chronic rhinosinusitis (CRS) is a chronic inflammatory condition affecting 10% to 15% of the population that presents commonly to both specialists and primary care physicians. [1] [2] [3] CRS is associated with a disease burden comparable in magnitude with that of other serious diseases, such as congestive heart failure, chronic obstructive pulmonary disease (COPD), and asthma. 4, 5 Unlike acute sinusitis, which is typically attributable to infection, CRS has multiple exogenous and endogenous causes that ultimately result in persistent inflammation of mucosal surfaces in the nose and paranasal sinuses. 6 The multiple symptomatic consequences of this chronic inflammation can result from impaired mucociliary clearance, abnormal ventilation and drainage of narrow crevices in the upper posterior nasal cavity and sinuses, production of inflammatory mediators, alterations in nitric oxide levels, and other abnormalities. 6 The 4 diagnostically defining symptoms of CRS (with or without nasal polyps [NPs]) include (1) facial pain or pressure, (2) persistent nasal congestion/ obstruction, (3) hyposmia/anosmia (loss of sense of smell), and (4) nasal discharge (typically purulent). However, multiple other symptoms, such as sleep dysfunction, headache, and disordered mood, are common and important. 7, 8 CRS is divided into 2 common subtypes: chronic rhinosinusitis with nasal polyps (CRSwNP) or CRS without NPs. 7, 8 NPs are benign bilateral lesions developing from chronically inflamed mucosa. 9, 10 NPs arise most commonly in the middle meatus or ostiomeatal complex (above the inferior turbinate or under the middle turbinate) behind the uncinate process. 11 NPs can exacerbate inflammatory tissue responses, and their bulk adds to airflow blockage. By obstructing sinus drainage and ventilation pathways, polyps also promote sinus inflammation and associated symptoms.
The chronic inflammation seen in patients with CRSwNP is frequently responsive to the broad-spectrum anti-inflammatory effects of corticosteroids. Short courses of oral corticosteroids usually relieve symptoms and reduce polyp bulk, but symptoms recur soon after discontinuation, and even short courses are associated with risks, especially when required multiple times a year. [13] [14] [15] [16] Topical intranasal corticosteroids are safer and generally recommended as both primary treatment and secondary prophylaxis against recurrence after surgery. 7, 8 Unfortunately, most patients with CRSwNP do not achieve satisfactory outcomes with currently available nasal corticosteroids. 17, 18 This has long been attributed to the inability of standard delivery mechanisms to consistently deliver medication to superior/posterior regions where sinus ostia drain and polyps originate. 19, 20 Consequently, surgery is often indicated after inadequate response to pharmacologic treatment. 7, 8, 21 Although surgery is effective in producing symptomatic benefit, recurrence of symptoms and polyps is common, often resulting in additional surgeries. 22, 23 Notably, topical medications are also an important adjunct to surgery, and topical corticosteroids are often continued after surgery to treat persistent or recurrent symptoms and reduce NP recurrence. 7, 8 The exhalation delivery system with fluticasone (EDS-FLU) uses a novel closed-palate mechanism designed to deliver medication to regions targeted in patients with CRS (Fig 1) . 24 Fluticasone is a potent corticosteroid with low bioavailability. The exhalation delivery system (EDS) is a new concept for intranasal drug delivery and has been shown to deliver a substantial fraction of medication past the head of the inferior turbinate and into the superior/posterior regions of the nasal passages, such as the ostiomeatal complex. The medication is a new formulation with no alcohol or fragrance and fluticasone concentration roughly double that of Flonase (fluticasone; GlaxoSmithKline, Research Triangle Park, NC). A previous pilot study with a different device suggested that EDS delivery of fluticasone was effective in reducing both polyp grade and symptoms, 25, 26 and a formal randomized comparative pharmacokinetic study has shown that EDS-FLU is not bioequivalent to a similar dose of fluticasone propionate nasal spray (Flonase), although it produces substantially lower systemic exposure than inhaled fluticasone propionate (Flovent HFA). 27 This trial was designed to assess EDS-FLU in a common but difficult-to-manage clinical presentation: patients with moderateto-severe CRSwNP, many of whom were previously treated with conventional corticosteroid nasal sprays, surgery, or both.
METHODS

Trial design and participants
This was a randomized, double-blind (DB) trial (see Appendix E1 in this article's Online Repository at www.jacionline.org for lists of sites, investigators, and recruitment and follow-up periods) undertaken in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki. Documents and procedures were approved by appropriate institutional review boards and ethics committees at each site; patients provided written informed consent before participation.
Eligible patients were 18 years or older with at least moderate symptoms of nasal congestion/obstruction, as reported by the subject (morning score > _2 using a 4-point scale [0, none; 1, mild; 2, moderate; and 3, severe] for > _5 of the 7 days during screening) and bilateral polyps. Patients with asthma or COPD were required to be stable (no exacerbations within 3 months), with limits on doses of inhaled corticosteroid (stable doses not exceeding 1000 mg/d beclomethasone [or equivalent] for at least 3 months before screening with plans to continue throughout the study). Exclusions included more than 5 sinonasal surgeries (lifetime) or surgery in the prior 6 months, septal perforation, and more than 1 episode of clinical epistaxis within 1 month. After week 4, nonsedating antihistamines were permitted as ''rescue medication.'' Entry (see Appendix E2 in this article's Online Repository at www.jacionline.org) and exclusion (see Appendix E3 in this article's Online Repository at www.jacionline.org) criteria, as well as prohibited (see Appendix E4 in this article's Online Repository at www.jacionline.org) and concomitant (see Appendix E5 in this article's Online Repository at www.jacionline.org) medications are listed in this article's Online Repository.
Intervention
After a 7-to 14-day, single-blind, EDS-placebo run-in period, patients entered a 16-week DB treatment phase. Patients completing the DB phase continued to an 8-week open-label (OL) period, during which all received 372-mg EDS-FLU twice daily but remained blind to prior treatment.
Randomization sequence, allocation, and blinding
Random sequence allocation was performed and concealed by an interactive Web-response system (1:1:1:1) to 93-, 186-, or 372-mg EDS-FLU or EDSplacebo for twice-daily use. Codes were generated centrally with a block size of 4. The Web-response system tracked enrollment, randomly assigned subjects to treatment groups, and managed study drug supplies.
An EDS-placebo product identical to EDS-FLU, except for fluticasone, with visually matching labeling was used to ensure adequate blinding and minimize performance and detection bias. Both formulations were free of alcohol or fragrance and included the same pH-and osmolality-adjusted vehicle formulation, excipients, and antimicrobial preservative system. During the single-blind run-in phase, only subjects were blind to study treatment. During the DB treatment phase of the study, subjects, the investigator, and study center personnel at each center and the sponsor or its designated personnel directly involved in the clinical study remained blind to study treatment.
Outcomes
Coprimary end points were (1) mean change in morning congestion/ obstruction score averaged over 7 days before the end of week 4 and (2) mean change in endoscopically assessed total polyp grade (summed from both sides, 0-to 3-point score on each side) at week 16. Symptoms were patient recorded using electronic diaries twice daily (morning and evening) and reported both as experienced at the moment of reporting (ie, instantaneous) and as recalled over the preceding 12 hours (ie, reflective). Diaries captured all 4 defining symptoms of CRS (congestion/obstruction, rhinorrhea, facial pain or pressure, and hyposmia). Polyp grade determined by using nasoendoscopy was based on extent of polyp tissue mass at the moment of observation relative to unequally spaced anatomic landmarks in 1 dimension: 0, no polyps; 1, not below the inferior border of the middle turbinate; 2, below the inferior border of the middle turbinate but not the inferior border of the inferior turbinate; and 3, below the lower inferior border of the inferior turbinate. 28 Responders were defined as having a 1-point or greater improvement, and complete response was defined as a grade of 0 (no polyps) in at least 1 nostril.
Prespecified secondary end points included objective measures of disease severity, subjective measures of quality of life (QoL), symptoms, and functioning and health economic outcomes (see Appendix E6 in this article's Online Repository at www.jacionline.org). Analyses included change from baseline over time in the 4 defining symptoms of CRS, Sino-Nasal Outcome Test (SNOT-22) score, 29, 30 Patient Global Impression of Change (PGIC) score, 31, 32 standardized surgical eligibility indicators assessment, peak nasal inspiratory flow, Medical Outcomes Study Sleep Scale-Revised (MOS-Sleep-R) score, 33 36-Item Short Form Health Survey (SF-36v2) score, 34 and Rhinosinusitis Disability Index score. 35 To facilitate assessment across multiple centers in multiple countries with multiple different health care systems, indicators for surgical eligibility were assessed by using standardized criteria, all of which were required concurrently: moderate-to-severe symptoms of congestion for 3 months or more, use of conventional topical steroids for 6 weeks or more, current or previous use of saline lavage for 6 weeks or more, and endoscopically visualized bilateral nasal polyposis of at least moderate severity (NP grading score > _2 in at least 1 nostril). These criteria were intended to serve as proxy indicators to identify patients who can reasonably be evaluated for surgical intervention, recognizing that the decision to proceed to surgery for an individual patient is complex and influenced by many factors. Accordingly, patients deemed ''eligible'' might or might not have been offered surgery.
Safety assessments included nasoendoscopy by a specialist at each time point, including active assessment and scoring for adverse events (AEs) of interest (eg, epistaxis, septal erosion, and mucosal candidiasis). Ophthalmologists performed tonometry and slit-lamp examination at screening and weeks 16 and 24.
Statistical methods
Assuming an SD of 1.9 by using a 2-sided t test at 5% significance with 90% power, a sample of 80 per group was determined to be sufficient to detect a 1.0 scale difference. Assumptions were based on prior studies with intranasal corticosteroids. 25, 26, [36] [37] [38] [39] [40] Between-group analyses were based on randomized treatment allocation. Safety analyses included data for all subjects who received a single dose of study medication, whereas efficacy analyses were based on the Full Analysis Set, which included all subjects who had baseline assessments of coprimary measures (polyp grade and morning congestion/ obstruction).
The first coprimary analysis (congestion) was an analysis of covariance model including baseline as a covariate and treatment group and country as fixed effects. For the second coprimary analysis (polyp grade), a mixed-effects model for repeated measures was used, using patients as the block factor for repeated measurements, with baseline bilateral polyp score as a covariate and treatment, country, visit, and interaction of treatment by visit as fixed effects. An unstructured covariance matrix was used for within-subject correlation modeling. For these primary analyses, missing data were imputed by using a pattern mixture model. Each active treatment group was compared with EDS-placebo for the coprimary variables. A fixed-sequence multiple-comparison procedure provided strong control of study-wide type I error for tests of multiple doses across both primary measures against EDS-placebo. The hierarchy was as follows: 372-mg EDS-FLU/congestion; 372-mg EDS-FLU/NP grade, 186-mg EDS-FLU/congestion; 186-mg EDS-FLU/NP grade, 93-mg EDS-FLU/ congestion; and 93-mg EDS-FLU/NP grade.
For prespecified secondary analyses, change from baseline for continuous end points was analyzed with either the mixed-effects model for repeated measures or analysis of covariance by using the analyses described for primary end points. From these models, the least-squares mean difference between each active treatment group and the EDS-placebo group, 95% CI, and nominal P value for difference were estimated by visit. For categorical variables, odds ratios were obtained from a generalized estimating equation model for binomial distribution, including treatment and country as fixed factors. Nominal P values were obtained from the generalized estimating equation model by using the x 2 test to compare each active group and EDS-placebo. Safety summaries were descriptive, and no formal statistical comparisons were performed.
RESULTS
A total of 323 patients were randomized, with 321 receiving at least 1 dose of study medication (safety analysis set) and 299 (92.6%) continuing from the DB into the OL phase. The EDS-placebo group had the highest dropout rate (12.5%) compared with 3.7%, 5.0%, and 0% in the 93-, 186-, and 372-mg EDS-FLU groups, respectively. (1) creates an airtight seal of the soft palate, isolating the nose from the mouth and lungs; (2) transfers proportional pressure into the nose; and (3) helps ''float'' medication around obstructions to deposit in high/deep sites in the nasal labyrinth, such as the ostiomeatal complex. The transferred pressure is proportional to varying exhalation force, counterbalancing pressure on the soft palate. This ensures a patent communication behind the nasal septum, allowing air to escape through the opposite nostril. Positive pressure expands passages narrowed by inflammation (vs negative pressure delivery [ie, sniffing]). Use is simple and quick. A patient inserts the nosepiece into one nostril and starts blowing through the mouthpiece. This elevates and seals the soft palate, as with inflating a balloon, separating the oral and nasal cavities. The patient completes use by pressing the bottle to actuate. This causes a coordination-reducing valve to release the exhaled breath concurrently with aerosol spray in a burst of naturally humidified air.
( Table I ). Additional baseline characteristics are detailed in Table I, Fig E1, and Table E1 in this article's Online Repository at www.jacionline.org. Baseline characteristics indicate that study patients were moderately to severely ill and that most had previously received treatment with corticosteroids, surgery, or both.
All doses of EDS-FLU significantly improved both coprimary end points (Table II) . The greatest response was in the 2 higher-dose EDS-FLU groups (186 and 372 mg), although this difference did not reach statistical significance versus the lower dose.
Polyp grade was statistically significantly improved in each EDS-FLU group at every time point from week 8 through week 24 (P < .05 vs EDS-placebo; Fig 3 and Table II) . By week 16, 63.0% to 69.1% of patients in the EDS-FLU groups had achieved response (> _1-point improvement) in polyp grade compared with 43.5% with EDS-placebo (P < _ .016, all comparisons; Table II ). The polyp elimination rate in at least 1 nostril increased with increasing treatment duration, reaching 13.6% in the 372-mg EDS-FLU group at week 16 compared with 4.3% with EDS-placebo and increasing to 28.2% at 24 weeks (vs 8.7% in the group receiving EDS-placebo for 16 weeks plus 372-mg EDS-FLU for 8 weeks, P < _ .014; Table II) .
Least-squares mean change in all 4 diagnostically defining symptoms (instantaneous morning) showed significantly greater treatment effect with EDS-FLU than EDS-placebo at all doses (Table II) . In addition to the primary time point, the difference was significant at all other time points with the 372-mg EDS-FLU dose Baseline instantaneous morning congestion and SNOT-22 data are from the full analysis set, whereas other data are from the intention-to-treat population. BID, Twice daily. *Does not include polyp removal surgeries through polypectomy only.
and nearly all time points at lower doses (Fig 4) . Reflective morning assessment of CRSwNP symptoms also showed that EDS-FLU significantly improved all defining symptoms at all time points at the 372-mg EDS-FLU dose and almost all time points at lower doses (Fig 1 and see Fig E1 and Table E1 ). With respect to impairment of sense of smell, the 372-mg dose consistently demonstrated the largest treatment benefit (P < .05, all assessments). Based on the primary symptom measure (congestion/ obstruction), the 186-and 372-mg EDS-FLU dose groups produced earlier onset of action (sustained daily statistical significance vs EDS-placebo at days 6 and 10, respectively) compared with EDS-FLU 93 mg (day 26). Evening assessments of symptoms demonstrated a similar pattern of improvement compared with morning assessments (data not shown). The SNOT-22 total score, assessing symptoms, QoL, and functioning, improved statistically significantly in the EDS-FLU groups compared with the EDS-placebo group at all time points from week 8 through the end of the DB phase (Table II) . PGIC results showed that most patients receiving EDS-FLU perceived meaningful treatment benefit: at the end of the DB phase 67.9% to 68.0% of patients receiving EDS-FLU rated their symptoms as ''much improved'' or ''very much improved'' compared with 31.5% receiving EDS-placebo (Table II) . At 24 weeks, the proportion of ''much'' and ''very much'' improved patients further increased, with the highest proportion of ''much'' or ''very much improved'' patients in the group originally randomized to 372-mg EDS-FLU (83.4%, Table II ). Other measures of wellbeing and perceived health, such as Rhinosinusitis Disability Index, SF-36v2, and MOS-Sleep-R sleep problems index scores improved significantly (Table II) . All doses of EDS-FLU also significantly reduced the proportion of patients with standardized indicators for surgical eligibility relative to EDS-placebo (P <.05, all comparisons; Table III ). Patients completed a medication evaluation questionnaire rating the use of their EDS at screening All patients received 372-mg EDS-FLU during the OL phase; thus, for week 24 assessments, the header columns indicate treatment sequences (ie, EDS-placebo followed by 372-mg EDS-FLU, 93-mg EDS-FLU followed by 372-mg EDS-FLU, 186-mg EDS-FLU followed by 372-mg EDS-FLU, and 372-mg EDS-FLU followed by 372-mg EDS-FLU). BID, Twice daily; OR, odds ratio; RSDI, Rhinosinusitis Disability Index. *Data are from the full analysis set with imputation. All patients received 372-mg EDS-FLU during the extension phase. àP < .001 versus EDS-placebo. §P < .05 versus EDS-placebo.
and follow-up (weeks 4, 16, and 24) by using Likert scales. At week 4, more than 85% of patients indicated that EDS-FLU was easy to use, increasing to greater than 90% at week 24.
AEs possibly attributable to EDS-FLU were local (not systemic). AEs occurring more often with EDS-FLU versus EDS-placebo and in at least 2% of patients were epistaxis, ulceration, ''nasal septum disorder'' (septal erythema), and headache (Table IV) . All ''septal ulceration'' AEs were reported as ''mild'' (ie, erosions), with the exception of 2 (2.4%) in the 372-mg EDS-FLU group that were ''moderate'' (ulceration) and 1 (1.3%) in the 93-mg group with a septal perforation. The perforation was identified at week 8 in a patient who underwent surgery (septoplasty) at the perforation site 4 months before entry. There were no differences between active/placebo groups in intraocular pressure, FEV 1 , or Asthma Control Test results in patients with asthma (patients' symptoms were well controlled at baseline), new identification of cataracts, or other laboratory or physical examination findings (data not shown).
During the DB phase, serious AEs were reported in 2 patients (1 in a patient receiving EDS-placebo: severe meningitis and sinusitis; and 1 in a patient receiving 372-mg EDS-FLU: positional vertigo); no serious AEs were reported during the OL phase. During the DB and OL phases, 10 patients had AEs leading to discontinuation: 2 (2.5%) receiving EDS-placebo, 1 (1.2%) receiving EDS-FLU 93-mg and 1 (1.3%) receiving EDS-FLU 186-mg during the DB phase; 3 between the DB and OL phases (all [4.0%] previously receiving EDS-FLU 186-mg); and 3 during the OL phase.
DISCUSSION
CRSwNP is a serious chronic inflammatory disease producing substantial symptom burden. Evidence suggests harm to QoL in multiple domains of comparable magnitude to many other serious chronic diseases, such as asthma, congestive heart failure, and COPD. 4, 5, 7, 8 Corticosteroids are potent nonspecific antiinflammatory agents; however, because of the short-lived benefits and adverse effects associated with systemic corticosteroids, current international treatment guidelines call for first-line use of topically acting intranasal corticosteroids. Unfortunately, symptom relief with currently approved intranasal corticosteroids is frequently inadequate. 17, 18 It has been long recognized that this inadequate efficacy is due in large part to ineffective or inconsistent delivery to key anatomic sites of disease. 19, 20, 41, 42 EDS-FLU uses a novel mechanism of action shown to deliver medication higher and deeper into the nasal passages than ordinary nasal sprays, including to the ostiomeatal complex, where sinus ostia normally ventilate and drain and where polyps usually originate. Patients entering this study had significant symptom burden despite almost universal prior corticosteroid and/or surgical treatment. In this common but difficult-to-treat population, EDS-FLU significantly improved the coprimary outcomes of congestion/obstruction symptoms and NP grade. EDS-FLU also substantially improved multiple other outcomes, including all 4 cardinal symptoms of CRSwNP (congestion/obstruction, pain or pressure, rhinorrhea, and hyposmia); measures of symptom burden, QoL measures, and functioning (SNOT-22, PGIC, RSDI, and SF-36); sleep (MOS-Sleep-R); and indicators for potential surgery. Objective assessments also improved significantly (eg, rates of NP elimination). Although this study was not powered to compare doses, the 186-and 372-mg twice-daily doses were consistently more efficacious and had an earlier onset of action compared with the 93-mg twice-daily dose. Mean polyp grade improvement monotonically increased over 24 weeks (16-week DB phase plus 8-week OL extension), suggesting that benefit increases with longer treatment duration.
Mucosal inflammation and swelling in regions posterior to the nasal valve and especially those superior to the inferior turbinate, including the middle meatus, directly cause symptoms. NPs arising from chronically inflamed surfaces in these areas can further increase disease burden by exacerbating physical obstruction, impairing sinus ventilation/drainage, blocking airflow, causing congestion and hyposmia, and generating chemotactic cytokines that exacerbate inflammation and edema. 9, 10 Medical elimination of NPs is difficult with current nasal sprays, which is unsurprising because polyps typically originate in the middle meatus, a region difficult for conventional nasal sprays to access reliably. 11, 19, 20, 41, 42 In this study 28% of patients receiving 372-mg EDS-FLU had polyp elimination in at least 1 nostril by week 24. The rate of complete response generally increased at successive time points from week 4 through the end of the DB phase and continued to increase with longer duration of exposure through 24 weeks. This is consistent with the hypothesis that EDS enables consistent delivery to superior/posterior target sites over prolonged periods of outpatient care and that longer treatment might be beneficial in achieving complete remission.
Surgery is known to produce clinically meaningful benefits in patients with this disease, and therefore the clinical relevance of the magnitude of improvement produced by EDS-FLU can be gauged against that benchmark. Treatment improvement measured by using SNOT-22, a validated and commonly used outcome measure in patients with CRS, was similar in magnitude to the improvement in a large cohort of patients undergoing surgery and notably larger than the reported minimal clinically important difference, suggesting that the magnitude of benefit with EDS-FLU is clinically meaningful. 30 This trial is not a direct comparison with surgical treatment, and this benchmarking serves only to help gauge the clinical meaningfulness of the observed magnitude of change. The clinical and not merely statistical importance of EDS-FLU treatment benefit is also directly informed by the large response observed in this trial on patient-reported outcomes, such as the PGIC.
The pattern and frequency of AEs was consistent with expectations for topical corticosteroids used in this population for this duration. [38] [39] [40] 43, 44 The most common AEs occurring more often with EDS-FLU were epistaxis, headache, mucosal erythema, or septal ulceration. The proportion of patients observed to have epistaxis, ulceration, or erythema did not increase over time with increasing duration of exposure.
Monoclonal antibodies that inhibit IgE or specific cytokines implicated in T H 2-mediated inflammation have been shown to shrink polyps and improve symptoms in patients with CRSwNP in whom conventional intranasal corticosteroids have failed. [45] [46] [47] This study suggests that EDS-FLU might offer an important and safe therapeutic step before systemic intervention with biologic medications, oral corticosteroids, or invasive surgery for patients not achieving satisfactory outcomes with conventional intranasal corticosteroids.
The EDS-placebo group change in polyp grade in this study (20.62 after 16 weeks) is similar to the placebo response in prior studies with a similar design, including method of polyp assessment, and duration. 38, 39 However, comparison with treatment effects in other studies is a challenge, particularly with regard to NP grade. Endoscopic polyp grading systems like the one used in this study are useful for identifying treatment benefit but have limitations. NPs are complex 3-dimensional structures; however, these systems score polyp burden in only 1 dimension Note: The denominator is the number of patients with an assessment at that time point. All patients received 372-mg EDS-FLU during the OL phase; thus, for week 24, the header columns indicate treatment sequences (ie, EDS-placebo > 372-mg EDS-FLU, 93-mg EDS-FLU > 372-mg EDS-FLU, 186-mg EDS-FLU > 372-mg EDS-FLU, and 372-mg EDS-FLU > 372-mg EDS-FLU). BID, Twice daily; N, total of number of patients randomized/enrolled/treated; n, number of patients in the subset at the given time point. *All patients received 372-mg EDS-FLU twice daily during the OL phase from weeks 16 to 24. For instance, some systems divide grade 3 into 2 grades (grade 3 and grade 4) or specify an increase in grade for NPs observed medial to the middle turbinate: these changes are likely to create an artifactual increase in the apparent numeric magnitude of treatment response. For these reasons, comparative interpretation of treatment effect across studies is greatly enhanced by considering multiple end points rather than simply polyp grade, particularly when either the method of assessment or baseline scores are different.
Assessment of symptom improvement in this study, including in the ''placebo'' comparator group, is also subject to some unique considerations. In this study the control group used an EDS device delivering a liquid formulation, which might be important because of the potential for direct benefits because of the EDS device and twice-daily, low-volume, high-velocity nasal lavage. In addition, data suggest the possibility that direct EDS device benefits (in all treatment groups) could be produced by the effects of carbon dioxide in exhaled breath (influencing inflammatory mediator and neuropeptide activity), through removal of nitric oxide, positive pressure, vibration, or change in pH. 24, [48] [49] [50] Symptoms associated with CRSwNP are typically responsive to treatment with corticosteroids. Although oral corticosteroids can provide broad symptomatic improvement along with polyp reduction, the effects tend to be short-lived after discontinuation, 13, 14 and multiple adverse effects have been described, including adrenal suppression, alteration in bone metabolism, 14 and rare but serious complications, such as avascular necrosis of the hip, after even short courses. 15, 16 Topically acting intranasal corticosteroids are much safer and therefore currently recommended as first-line treatment for CRS.
This pivotal study does not provide a direct comparison of EDS-FLU with equivalent doses of a topical steroid delivered by means of conventional nasal spray. Although a controlled comparison trial would be of interest, it faces important challenges. For example, although randomization would be straightforward, double-blinding would not. A double-dummy trial (ie, all patients use both devices, 1 active and 1 placebo, twice daily) would raise challenging issues of washout (ie, the first device's payload risks being washed out by the second device's payload) and introduce practical issues of patient adherence over long treatment periods. However, conventional topical nasal steroids have been subjected to extensive prior study, including at comparable doses. Absent gold standard direct comparison, it is reasonable to examine what is known about their benefits.
The efficacy of prior intranasal steroids (as a group) for treatment of CRS was evaluated in a 2016 Cochrane review. 43 Most evidence was from studies in patients with CRSwNP. The authors found little evidence of benefit on QoL measures (very low-quality evidence), some evidence for symptom improvement (low-quality evidence), moderate improvement in congestion and small benefit in rhinorrhea (moderate-quality evidence), and even smaller or inconsistent evidence of benefit for hyposmia/anosmia and facial pain/pressure. This trial showed that EDS-FLU produces a clinically and statistically significant benefit on QoL and on all 4 cardinal symptoms, with a magnitude of effect on most symptoms that is greater than the 95% CI reported in the Cochrane review for previous intranasal corticosteroids. These findings should be confirmed in a second study. Additional research could help inform clinical use (eg, use in patients with CRS without NPs or in subpopulations like patients with prior surgery).
This randomized controlled trial was performed in a population with moderate-to-severe disease, many of whom had previously used intranasal corticosteroids, undergone surgery, or both. It demonstrates that EDS-FLU produces significant improvement in a broad range of symptoms, QoL measures, functioning, and NP grade in most treated patients and ''medical polypectomy'' in some patients and that improvements increase with longer duration of treatment. These results suggest that by using a novel mechanism of action to better deliver topically acting corticosteroid to target intranasal sites, EDS-FLU can offer significant new benefits in the medical management of CRSwNP. Risk/benefit and evidence-based treatment considerations in the context of treatment alternatives suggest that EDS-FLU might emerge as a component of the standard-of-care treatment pathway for maximizing appropriate medical therapy for this population.
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Clinical implications: The results of NAVIGATE II show that EDS-FLU significantly improves treatment of CRSwNP and offers an effective and well-tolerated option, including for patients who do not obtain satisfactory relief with standard intranasal corticosteroids. BID, Twice daily; n, total of number of patients randomized/enrolled/treated is shown. *Includes spontaneous adverse reaction reports. 
